JPH0576960B2 - - Google Patents

Info

Publication number
JPH0576960B2
JPH0576960B2 JP61500863A JP50086386A JPH0576960B2 JP H0576960 B2 JPH0576960 B2 JP H0576960B2 JP 61500863 A JP61500863 A JP 61500863A JP 50086386 A JP50086386 A JP 50086386A JP H0576960 B2 JPH0576960 B2 JP H0576960B2
Authority
JP
Japan
Prior art keywords
antibody
modified
peg
mpeg
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61500863A
Other languages
English (en)
Japanese (ja)
Other versions
JPS62501449A (ja
Inventor
Toomasu Bii Tomashi
Uiriamu Eru Andaason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUNIBASHITEI OBU NYUU MEKISHIK
YUNIBASHITEI OBU NYUU MEKISHIKO
Original Assignee
YUNIBASHITEI OBU NYUU MEKISHIK
YUNIBASHITEI OBU NYUU MEKISHIKO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YUNIBASHITEI OBU NYUU MEKISHIK, YUNIBASHITEI OBU NYUU MEKISHIKO filed Critical YUNIBASHITEI OBU NYUU MEKISHIK
Publication of JPS62501449A publication Critical patent/JPS62501449A/ja
Publication of JPH0576960B2 publication Critical patent/JPH0576960B2/ja
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP61500863A 1984-12-31 1985-12-31 Ｐｅｇ修飾抗体及びその製造方法 Granted JPS62501449A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/687,811 US4732863A (en) 1984-12-31 1984-12-31 PEG-modified antibody with reduced affinity for cell surface Fc receptors
US687811 1984-12-31

Publications (2)

Publication Number Publication Date
JPS62501449A JPS62501449A (ja) 1987-06-11
JPH0576960B2 true JPH0576960B2 (enExample) 1993-10-25

Family

ID=24761953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61500863A Granted JPS62501449A (ja) 1984-12-31 1985-12-31 Ｐｅｇ修飾抗体及びその製造方法

Country Status (5)

Country Link
US (1) US4732863A (enExample)
JP (1) JPS62501449A (enExample)
DE (2) DE3590392C2 (enExample)
GB (1) GB2181433B (enExample)
WO (1) WO1986004145A1 (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
EP0315456B1 (en) * 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
FR2626373B1 (fr) * 1988-01-22 1993-10-15 Stabiligen Procede de preparation d'un traceur stable et traceur obtenu
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB8909711D0 (en) * 1989-04-27 1989-06-14 Secr Defence Optical beam steering device
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
DE4004296A1 (de) * 1990-02-13 1991-08-14 Hoechst Ag Verbesserte markierte haptene, verfahren zu deren herstellung sowie verwendung dieser markierten haptene in immunoassays
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
SE468238B (sv) * 1990-02-28 1992-11-30 Sten Ohlson Laekemedel med svag affinitet
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5885570A (en) * 1991-01-23 1999-03-23 The General Hospital Corporation Induction of tolerance with modified immunogens
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU8001694A (en) * 1993-11-03 1995-05-23 University Of Manitoba Cell control and suppression
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
IT1268955B1 (it) * 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl Esteri attivi di polisaccaridi carbossilici
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
DE69637383T2 (de) 1995-05-10 2008-12-11 Kyowa Hakko Kogyo Co., Ltd. Cytotoxinkonjugate umfassend dipeptide
US5874500A (en) * 1995-12-18 1999-02-23 Cohesion Technologies, Inc. Crosslinked polymer compositions and methods for their use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
AU1555297A (en) * 1996-02-01 1997-08-22 Biomedical Frontiers, Inc. Antigenic modulation of cells
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
CA2280866A1 (en) 1997-02-13 1998-08-20 Lxr Biotechnology Inc. Organ preservation solution
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1415998A3 (en) 1997-02-21 2005-11-23 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
CN1250566C (zh) * 1997-06-06 2006-04-12 协和发酵工业株式会社 化学修饰的多肽
DE19748489A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
AU2742499A (en) 1998-03-26 1999-10-18 Procter & Gamble Company, The Serine protease variants having amino acid substitutions
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
EP1107998B1 (en) * 1998-08-28 2004-02-04 Gryphon Sciences Method for the preparation of polyamide chains of precise length, their conjugates with proteins
ATE390441T1 (de) * 1998-10-30 2008-04-15 Novozymes As Niedrigallergene proteinvarianten
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
AU5928400A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Protease conjugates having sterically protected clip sites
CN1399677A (zh) 1999-07-22 2003-02-26 宝洁公司 在确定表位区有氨基酸取代的枯草杆菌蛋白酶变体
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
MXPA02000843A (es) 1999-07-22 2002-07-30 Procter & Gamble Variantes de subtilisina proteasa que tienen supresiones de aminoacidos y sustituciones en regiones de epitope definidas.
DE60025241T2 (de) * 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
EP2275447A1 (en) 1999-11-24 2011-01-19 Schering Corporation Methods of inhibiting metastasis
ATE416782T1 (de) 2000-04-18 2008-12-15 Schering Corp Medizinische verwendung von il-174 agonisten und antagonisten
HU230437B1 (hu) * 2000-06-02 2016-06-28 Board Of Regents, The University Of Texas System Etilén-dicisztein(EC)-drog-konjugátumok, készítmények és eljárások betegség szövet-specifikus leképzésére
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
CA2423850C (en) 2000-10-09 2017-07-04 Isis Innovation Limited Therapeutic antibodies
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US20030186875A1 (en) 2002-02-01 2003-10-02 Rene De Waal Malefyt Uses of mammalian cytokine; related reagents
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP2287198A3 (en) 2002-03-13 2011-05-25 Biogen Idec MA Inc. Anti-alpha V beta 6 antibodies
AU2003241279A1 (en) * 2002-03-26 2003-10-13 Biosynexus Incorporated Antimicrobial polymer conjugates
WO2004044227A2 (en) * 2002-11-07 2004-05-27 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
AU2003303513A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
WO2004097019A1 (ja) * 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
KR101148445B1 (ko) 2004-04-28 2012-07-05 안지오디바이스 인터내셔널 게엠베하 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및 이와 관련된 제조 및 사용 방법
CA2579790A1 (en) * 2004-07-30 2006-02-09 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof
WO2006034128A2 (en) 2004-09-17 2006-03-30 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
SG2014009484A (en) 2005-04-11 2014-05-29 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
CA2606018A1 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
EP1877101B1 (en) * 2005-04-28 2016-11-16 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US7981690B2 (en) * 2005-11-18 2011-07-19 Nitto Boseki Co., Ltd. Method of assaying antigen and kit to be used therein
DK2963011T3 (en) * 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
CA2648582C (en) 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2010078376A2 (en) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
US20130137645A1 (en) * 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
CN103261087B (zh) * 2010-10-18 2018-08-10 华盛顿大学商业化中心 发色聚合物点
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR20150133576A (ko) * 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10632180B2 (en) 2015-02-06 2020-04-28 The Regents Of The University Of California Methods and compositions for improved cognition
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2019036433A2 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
US20220118060A1 (en) 2019-02-04 2022-04-21 The Regents Of The University Of California Exercise-induced circulatory factors for amelioration of cognitive, neurological, and regenerative dysfunction during aging
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN110672836B (zh) * 2019-09-30 2023-03-21 香港大德昌龙生物科技有限公司 磁珠包被物及其制备方法和应用、检测试剂盒
WO2021163272A2 (en) 2020-02-12 2021-08-19 The Regents Of The University Of California Platelet factors and cognitive improvement
WO2024092238A1 (en) 2022-10-28 2024-05-02 Unity Biotechnology, Inc. Klotho polypeptide or polynucleotide for improving cognition
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
DE2856939A1 (de) * 1978-12-13 1980-07-03 Schura Blutderivate Gmbh & Co Verfahren zur gewinnung von intravenoes-vertraeglichen gammaglobulinen
JPS56113713A (en) * 1980-02-14 1981-09-07 Chemo Sero Therapeut Res Inst Preparation of immunoglobulin with high content of monomer
JPS56163456A (en) * 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4427653A (en) * 1981-01-26 1984-01-24 President And Fellows Of Harvard College Method of making monoclonal antibodies
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤

Also Published As

Publication number Publication date
GB8602672D0 (en) 1986-03-12
DE3590392C2 (enExample) 1993-01-14
WO1986004145A1 (en) 1986-07-17
GB2181433A (en) 1987-04-23
JPS62501449A (ja) 1987-06-11
DE3590392T (enExample) 1988-10-27
GB2181433B (en) 1989-01-05
US4732863A (en) 1988-03-22

Similar Documents

Publication Publication Date Title
JPH0576960B2 (enExample)
JPS63500524A (ja) マイコバクテリウム感染検出合成ポリペプチド
US5035995A (en) Test method involving substance-conjugated complement component C1q
JPH0678359B2 (ja) エプスタイン、バールウィルス核抗原と免疫反応する抗体を産生する化学的に合成されたポリペプチド
JPH04503600A (ja) 抗インターロイキン―１α及び―１βのモノクローナル抗体、その製法、ならびに前記抗体類の、インターロイキン―１α及び―１βの検出と治療への応用
JPS6357599A (ja) イヌ心糸状虫ワクチンおよび診断試験
Gunasekera et al. Stabilized cyclic peptides as scavengers of autoantibodies: neutralization of anticitrullinated protein/peptide antibodies in rheumatoid arthritis
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
EP0203089A1 (en) Monoclonal antibodies and their use
Kobayashi et al. Detection of Fcγ binding protein antigen in human sera and its relation with autoimmune diseases
US6541275B1 (en) Immunoassay for F1.2 prothrombin fragment
Krilis et al. Standardization of antigen E in ragweed pollen extracts using a monoclonal antibody-based enzyme immunoassay
PT676965E (pt) Método para reduzir a imunogenicidade da região variável de anticorpos
Anderson et al. Polymer modification of antibody to eliminate immune complex and Fc binding
JP3154724B2 (ja) 下痢性貝毒に特異的なモノクローナル抗体、ハイブリドーマ及び下痢性貝毒の検出方法
Prasad et al. Detection of antimicrofilarial ES antigen-antibody in immune complexes in Bancroftian filariasis by enzyme immunoassay
JPS62500586A (ja) モノクロ−ナル抗体およびその用途
AU726344B2 (en) High fluorescence specific immune enhancing factor and methods of use for same
NL8801227A (nl) Antilichamen tegen fibrine; voor de bereiding van de antilichamen te gebruiken immunogeen, werkwijze voor het bepalen van fibrine met de antilichamen en farmaceutisch preparaat op basis van de antilichamen.
JP3036545B2 (ja) モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法
JPS6229969A (ja) 非接触性細胞表面抗原に特異的な抗体を生産するハイブリド−マを選別する方法
CN100489531C (zh) 一种检测多拉菌素的方法及其专用酶联免疫试剂盒
JP4422291B2 (ja) ヒトメダラシンの免疫学的測定方法
EP0177023A2 (en) Substance-conjugated complement component C1q
JPWO2006004207A1 (ja) 抗シノビオリン抗体